Impact of pre-transplantation exposure to immunosuppressive agents on lung transplant outcomes in interstitial lung disease
Transplant International · 10.06.2026 · 39
DOI: 10.3389/ti.2026.16549 ↗Kurz gefasst
Fachartikel in der Zeitschrift Transplant International, online erschienen am 10.06.2026. Verfasst von Karim Tazibet und 19 weiteren Autor:innen. Beteiligte Einrichtung: Service de Pneumologie et Transplantation Pulmonaire, AP-HP, Hôpital Bichat, Paris, France. Hauptthemen laut MEDLINE: Lung Transplantation, Lung Diseases, Interstitial, Immunosuppressive Agents. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Fibrosing interstitial lung diseases (ILDs) are the leading cause of lung transplantation (LTx), with worse results than other indications. We hypothesised that exposure to non-steroidal immunosuppressive agents (IAs) in the year preceding LTx for ILD may result in poorer early outcomes. We retrospectively analysed adults who underwent LTx for ILD from April 2011 to June 2024 in our institution and compared patients who received IA within 1 year before LTx to those who did not (systemic steroids exposure was used to adjust analysis). The primary outcome was 12-month retransplantation-free survival. Among 209 patients included, 76 (36%) had received IA within 1 year of LTx, and these patients had significantly worse 12-month retransplantation-free survival on multivariate analysis (62% vs. 80%; HR 1.99, 95%CI [1.11–3.56], p = 0.022); IA exposure increased the odds of grade 3 PGD (OR 3.20 [1.42–7.45], p = 0.005), bronchovascular fistula (OR 9.43, 95% CI [1.48–183], p = 0.042), pneumonia episodes in the first 6 months (median 2 [IQR 1-4] vs. 1 [0.5–2.5], p = 0.001), cytomegalovirus viremia under prophylaxis (21% vs. 5.2%, p = 0.005) and incidence of ganciclovir-resistant cytomegalovirus (14% vs. 3.2%, p = 0.021). In conclusion, IA exposure in the year before LTx leads to early complications and worse 12-month survival.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Service de Pneumologie et Transplantation Pulmonaire, AP-HP, Hôpital Bichat, Paris, France.
- Service de Pneumologie et Immuno-allergologie, Univ. Lille, CHU Lille, Lille, France.
- INSERM, UMR 1149, Centre de Recherche sur l'inflammation, Université Paris Cité, Paris, France.
- Service de Réanimation Chirurgicale, AP-HP, Hôpital Bichat, Paris, France.
- Service de Physiologie, AP-HP, Hôpital Bichat, Paris, France.
- Service de Réadaptation Respiratoire, AP-HP, Hôpital Bichat, Paris, France.
Zitieren
APA
Tazibet, K., Bunel, V., Mal, H., Goletto, T., Halitim, P., Morer, L., Mouren, D., Salpin, M., Sandot, A., Weisenburger, G., Montravers, P., Atchade, E., Tanaka, S., Frija, J., Hajouji, L., Castier, Y., Mordant, P., Crestani, B., Borie, R., & El Husseini, K. (2026). Impact of pre-transplantation exposure to immunosuppressive agents on lung transplant outcomes in interstitial lung disease. Transplant International, 39. https://doi.org/10.3389/ti.2026.16549
Vancouver
Tazibet K, Bunel V, Mal H, Goletto T, Halitim P, Morer L, et al. Impact of pre-transplantation exposure to immunosuppressive agents on lung transplant outcomes in interstitial lung disease. Transplant International. 2026;39. doi:10.3389/ti.2026.16549
BibTeX
@article{Tazibet2026,
author = {Tazibet, Karim and Bunel, Vincent and Mal, Hervé and Goletto, Tiphaine and Halitim, Pierre and Morer, Lise and Mouren, Domitille and Salpin, Mathilde and Sandot, Adèle and Weisenburger, Gaëlle and Montravers, Philippe and Atchade, Enora and Tanaka, Sébastien and Frija, Justine and Hajouji, Linda and Castier, Yves and Mordant, Pierre and Crestani, Bruno and Borie, Raphaël and El Husseini, Kinan},
title = {Impact of pre-transplantation exposure to immunosuppressive agents on lung transplant outcomes in interstitial lung disease},
journal = {Transplant International},
year = {2026},
volume = {39},
doi = {10.3389/ti.2026.16549}
}
EUVIMED